Process of repeating items in a self-similar way
POPULARITY
16 episodes with Recursion
5 episodes with Recursion
4 episodes with Recursion
3 episodes with Recursion
4 episodes with Recursion
4 episodes with Recursion
5 episodes with Recursion
2 episodes with Recursion
2 episodes with Recursion
Recursion by Blake Crouch Andy and Dani are stuck reliving their lives again... and again... and again. The time travel theories? Pretty cool. But is that enough to carry a whole book? (Spoiler: the old guy says no.) So how much do you really need to care about characters for a story to land? And more importantly... how many drinks did we have while figuring it out?Trigger warning: This episode includes light discussion of self-harm and suicidal thoughts, as portrayed in the book. If you or someone you know is struggling, help is available. Call or text 988 to reach the Suicide & Crisis Lifeline. You're not alone.
Eric relays his dispatch from Dimension Capital's biotech summit in Park City, where the crowd was much more academic than the conferences we usually attend. Biotech stocks aren't doing great, meanwhile university funding cuts could spell trouble for drug research. Still, people were rosy about AI tools. We also took a temperature check on the state of fintech, which investors tell us is mixed. Everyone's hopeful about IPOs and streamlined stablecoins, but the dollar getting destabilized by the tariffs has some investors skittish. Later in the episode, Madeline explains how Trump's crackdown on immigration is spooking startup founders and employees. Timestamps: 00:42 Lineup of our upcoming fintech summit02:02 Eric's dispatch from Dimension Capital and Recursion's biotech summit09:22 Fintech IPOs and stablecoins en vogue18:50 Heightened immigration enforcement spooks startup employees
Strategy consultant turned writer Natasha Joukovsky joins me to discuss why bourgeois comfort is more conducive to writing than you think, why choice-plots make for better fiction, the eyerolling prevalence of manufactured nonchalance, our shared distaste for Atlantis Bahamas, and MUCH more! I hope you enjoy this conversation as much as I did. For the full transcript, episode takeaways, and bucketloads of other goodies designed to make you go, “Hmm, that's interesting!”, check out our Substack. Important Links: Natasha's Website Natasha's Substack The Portrait of a Mirror Show Notes: “You can do everything, just not at the same time” It's Recursion All the Way Down Pretending to Read vs Actually Reading Manufactured Nonchalance as a Status Signal Counter-Signalling, Fake-Famous & Jim's Cursed Trip to Atlantis Bahamas On No-Choice Plots & Writing in Service of Beauty The Self-Deception of Status Hunting Why Bourgeois Comfort is More Conducive to Art Than You Think Natasha's Next Book “We don't do auctions” Natasha as World Empress Books Mentioned: The Portrait of a Mirror; by Natasha Joukovsky The novels of Jane Austen Status Anxiety; by Alain de Botton The Love Song of J. Alfred Prufrock (poem); by T.S. Eliot Class: A Guide Through the American Status System; by Paul Fussell Gödel, Escher, Bach: An Eternal Golden Braid; by Douglas R. Hofstadter Ulysses; by James Joyce Metamorphosis; by Franz Kafka Beloved; by Toni Morrison In Search of Lost Time (Remembrance of Things Past); by Marcel Proust Collective Illusions; by Todd Rose The Status Game; by Will Storr Anna Karenina; by Leo Tolstoy The Theory of the Leisure Class; by Thorstein Veblen A Little Life; by Hanya Yanagihara
This is Derek Miller, Speaking on Business. Utah's life sciences industry is a key driver of our state's economy, and BioUtah serves as its dedicated trade association — working to ensure the state remains a leader in life sciences innovation. President and CEO, Kelvyn Cullimore, joins us with more. Kelvyn Cullimore: As one of the fastest-growing biotech hubs in the nation, Utah's life sciences industry generates over 22 billion dollars in GDP, 182,000 jobs and wages at nearly 50 percent higher than the state average. This industry is comprised of medical device and diagnostic manufacturers, pharmaceutical companies, medical labs, and research facilities, whose products touch millions of patients each year and help fuel the Utah economy. BioUtah members include medical device manufacturers like Merit Medical, BD, Stryker and Fresenius; medical laboratories like ARUP and Nelson Labs; and pharmaceutical developers Teva, Denali, and Halia Therapeutics, among many others. Utah punches well above its weight in bringing innovative medical technologies to patients worldwide, such as brain and computer interface technology from Blackrock Neurotech, innovative heart valve replacement systems by Edwards Lifesciences, AI for enhanced drug discovery by Recursion, and Nusano's radioisotope technology, and so much more. Derek Miller: BioUtah is on a mission to build awareness and advance Utah's innovative, patient-focused life sciences industry. Through their work, they're making a real difference in the lives of Utahns. Learn more at BioUtah.org today. I'm Derek Miller, with the Salt Lake Chamber, Speaking on Business. Originally aired: 5/13/25
Send us a textDr. Martin Brenner, DVM, Ph.D. is Chief Executive Officer and Chief Scientific Officer of iBio ( https://ibioinc.com/team/martin-brenner-dvm-ph-d/ ), a biotech company developing the next generation of cardiometabolic and obesity medicines to promote higher quality weight loss and enhance overall metabolic health and function, as well as a pipeline of therapeutic candidates in immuno-oncology for some of the most-difficult-to-treat cancers, including solid tumors in lung, colorectal, and breast cancer, head and neck cancer, pancreatic cancer and glioblastoma, a fast-growing brain tumor. Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca, Eli Lilly and Company, Pfizer Inc., and Merck Research Laboratories. Most recently, Dr. Brenner served as the CSO at Pfenex Inc., which, using its patented Pfēnex Expression Technology® platform, created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Pfenex was acquired by Ligand Pharmaceuticals Incorporated for approximately $516 million in October 2020. Previously, Dr. Brenner served as the CSO at Recursion Pharmaceuticals, Inc., a company focused on accelerating drug discovery for rare diseases and diseases with high unmet medical need. Prior to his time at Recursion, Dr. Brenner was Vice President and Head of Research & Early Development at Stoke Therapeutics, Inc., a biotechnology company using antisense oligonucleotides to increase gene expression for the treatment of rare diseases. Prior to Stoke, Dr. Brenner was Executive Director at Merck, where he built a biotech unit from scratch, focusing his team's research on diabetes and nonalcoholic steatohepatitis (NASH). Earlier in his career, Dr. Brenner was the Senior Director and Head of cardiovascular, renal, and metabolism (CVRM) biosciences at AstraZeneca. In addition, Dr. Brenner was an Associate Research Fellow at Pfizer where he led the islet biology and in vivo pharmacology in the CVMED Target Exploration Unit before assuming the role of Head of the Insulin Resistance Group.Dr. Brenner has a DVM, Veterinary Medicine, Ludwig-Maximilians-Universität München and a Ph.D., Pharmacology Tieraerztliche Hochschule Hannover.#MartinBrenner #iBio #Cardiometabolic #Obesity #Medicines #WeightLoss #MetabolicHealth #ImmunoOncology #GLP1 #BispecificAntibodies #ArtificialIntelligence #TransformingGrowthFactorBeta #Myostatin #ActivinA #ActivinE #MuscleMass #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
Today's guest is Najat Khan, Chief R&D Officer and Chief Commercial Officer at Recursion Pharmaceuticals.Recursion is widely recognized as one of the most visible—and so far, most successful—companies to emerge from the tech-bio movement. Many consider it the current industry leader.It has become an iconic name in the field of artificial intelligence for drug discovery.TPM E44 highlights >Episode 44 links:Najat Khan on LinkedInRecursion
This week on Careers in Discovery, we welcome back Dave Hallett, now Chief Scientific Officer at Recursion, following the recent merger with Exscientia. The last five years have been transformative for Dave, from leading AI-driven drug discovery at Exscientia to navigating one of Biotech's biggest IPOs and stepping into the CEO role in a challenging market. Now, he's focused on proving that AI-designed medicines can deliver real impact, with clinical results beginning to emerge. We discuss the evolution of AI in drug discovery, the lessons Dave has learned leading a publicly listed company, and why the industry must focus on reducing drug development failure rates to make new medicines more accessible. A fascinating conversation with a leader at the forefront of Biotech innovation.
Narset and Elspeth venture into the dragonstorms and find a new mystery within them.Written by Cassandra KhawNarrated by Harless SnyderRead the Story: "Episode 5: Recursion"Preorder Tarkir: Dragonstorm: mtg.social/MagicStoryTDM
Chandana Haque is the Executive Director of Altitude Lab, a healthcare startup accelerator building a community of diverse entrepreneurs in Utah. Altitude Lab was cofounded in 2020 by Chandana and Chris Gibson, the co-founder & CEO of Recursion in Salt Lake City. They recently announced the launch of a pre-seed venture fund aimed at supporting early-stage biotech startups impacted by recent federal funding policy shifts. This pre-seed venture fund is dedicated to funding the highest impact ideas transitioning from basic research to industry. In partnership with Altitude Lab, they provide capital, lab space, and mentorship to high-potential SBIR reviewed companies, offering continuity for startups affected by recent funding policy changes while strengthening Salt Lake City's position as a national biotech hub. We talk about the Altitude fund, Altitude lab, lessons learned from other ecosystems; support from Recursion, better ways to support healthcare founders and many other topics. Shownotes Altitude lab fund: a pre-seed venture fund dedicated to funding the highest impact ideas transitioning from basic research to industry. Fund announcement: https://ir.recursion.com/news-releases/news-release-details/altitude-lab-launches-pre-seed-venture-fund-anchored-recursion Altitude labs: a health care accelerator building a community of diverse entrepreneurs in Utah Lessons learned (and unlearned) from Boston and Bay Area startup ecosystems Criteria for selection: Technology vs market readiness Founder fit, connecting founders to the right resources Turning a scrappy startup to a fundable one Overhyped areas in biotech Finding winners and lost opportunities Support from Recursion Pharma Supporting diversity: Anecdotes of diverse founders Support from the University of Utah
Send Everyday AI and Jordan a text message(Almost) Everyone hates the medical system. It's slow. It's expensive. It's archaic. GenAI is starting to change that. Find out how from an industry leader. Putting patients first with medical AI.Newsletter: Sign up for our free daily newsletterMore on this Episode: Episode PageJoin the discussion: Ask Jordan and Lina questions on AI biasUpcoming Episodes: Check out the upcoming Everyday AI Livestream lineupWebsite: YourEverydayAI.comEmail The Show: info@youreverydayai.comConnect with Jordan on LinkedInTopics Covered in This Episode:Introduction to Everyday AI ShowGeneral Discussion on AI in the Medical FieldOverview of Recursion and Lina Nilsson's RoleAdvancements and Impact of Medical AIRole of Large Language Models (LLMs) and AI Models in Medical AIPredictive and Preventive Applications of AI in HealthcareFuture Directions and Considerations in Medical AIConclusion and Final ThoughtsTimestamps: 00:00 Everyday AI Podcast Intro05:05 CRISPR: Revolutionary Genome Editing Technology08:10 Streamline AI Strategy, Achieve ROI13:01 Data-Driven Science Evolution14:42 Reducing Drug Costs with AI17:55 "LLMs Revolutionize Scientific Research"23:45 AI Advancements May Double Lifespan25:23 AI-Driven Drug Discovery InsightsKeywords: AI, drug discovery, generative AI, machine learning, medical field, healthcare, Recursion, CRISPR, biotechnology, models, human genome, dataset, protein structure, large language models, transformers, FDA, pharmaceuticals, rare diseases, clinical trials, data-driven, drug approval, artificial intelligence, patient care, healthcare affordability, innovation, medicine, bioinformatics, aging, disease prevention, scientific research. Ready for ROI on GenAI? Go to youreverydayai.com/partner
On this episode of Currently Reading, Kaytee and Meredith are discussing: Bookish Moments: Kindle samples and getting new indie bookstores Current Reads: all the great, interesting, and/or terrible stuff we've been reading lately Deep Dive: six star books to which we will take no criticism from anyone The Fountain: we visit our perfect fountain to make wishes about our reading lives Show notes are time-stamped below for your convenience. Read the transcript of the episode (this link only works on the main site) . . . . 1:01 - Ad For Ourselves 1:18 - Currently Reading Patreon 1:34 - An Unlikely Story 2:35 - @anunlikelystory on Instagram 3:37 - Our Bookish Moments Of The Week 6:48 - Literally, A Bookshop 7:54 - @Literallybookshop on Instagram 8:52 - Our Current Reads 9:23 - The Seven Sisters by Lucinda Riley (Meredith) 16:32 - All the Right Notes by Dominic Lim (Kaytee) 16:40 - Tucson Festival of Books 2025 19:52 - Arsenic and Adobo by Mia P. Manasala 20:13 - This Savage Song by Victoria Schwab (Meredith) 21:47 - A Darker Shade of Magic by V.E. Schwab 23:20 - The Invisible Life of Addie LaRue by V.E. Schwab 23:49 - They Came for the Schools by Mike Hixenbaugh (Kaytee) 24:11 - Southlake Podcast 27:46 - Past Crimes by Jason Pinter (Meredith) 29:44 - Ready Player One by Ernest Cline 31:06 - Recursion by Blake Crouch 31:40 - The Swifts: A Gallery of Rogues by Beth Lincoln (Kaytee) 31:49 - The Swifts: A Dictionary of Scoundrels by Beth Lincoln 35:11 - Our Six Star Reads 36:08 - The Sparrow by Mary Doria Russell 37:29 - The Count of Monte Cristo by Alexandre Dumas 37:33 - A Gentleman in Moscow by Amor Towles 40:17 - Happy Place by Emily Henry 42:32 - The Home-Maker by Dorothy Canfield Fisher 42:37 - The Ten Thousand Doors of January by Alix E. Harrow 42:38 - In This House of Brede by Rumer Godden 42:41 - The Stand by Stephen King 42:43 - The Shell Seekers by Rosamunde Pilcher 42:44 - A Curse So Dark and Lonely by Brigid Kemmerer 44:44 - All the Lonely People by Mike Gayle 45:00 - This Is How It Always Is by Laurie Frankel 45:09 - Castle of Water by Dane Huckelbridge 45:13 - Project Hail Mary by Andy Weir 45:14 - Black Cake by Charmaine Wilkerson 45:17 - Babel by R.F. Kuang 45:38 - Lobizona by Romina Garber Russell 45:43 - Cazadora by Romina Garber Russell 49:14 - The Bookish Life of Nina Hill by Abbi Waxman 49:49 - The Song of Achilles by Madeline Miller 51:22 - Meet Us At The Fountain 51:43 - Sarah's Bookshelves Live 51:53 - I want everyone to listen to episode 188 of Sarah's Bookshelves Live if you enjoy fantasy reading. (Meredith) 51:54 - Sarah's Bookshelves Live episode 188 53:09 - I wish for a book aggregator that would house all book covers of all books so we could compare easily and find the ones we want to purchase quickly without having to browse multiple sites. (Kaytee) 54:09 - Greenwood by Michael Christie Support Us: Become a Bookish Friend | Grab Some Merch Shop Bookshop dot org | Shop Amazon Bookish Friends Receive: The Indie Press List with a curated list of five books hand sold by the indie of the month. March's IPL comes to you from our tried and true partner, An Unlikely Story in Plainville, MA. Love and Chili Peppers with Kaytee and Rebekah - romance lovers get their due with this special episode focused entirely on the best selling genre fiction in the business. All Things Murderful with Meredith and Elizabeth - special content for the scary-lovers, brought to you with the behind-the-scenes insights of an independent bookseller From the Editor's Desk with Kaytee and Bunmi Ishola - a quarterly peek behind the curtain at the publishing industry The Bookish Friends Facebook Group - where you can build community with bookish friends from around the globe as well as our hosts Connect With Us: The Show: Instagram | Website | Email | Threads The Hosts and Regulars: Meredith | Kaytee | Mary | Roxanna Production and Editing: Megan Phouthavong Evans Affiliate Disclosure: All affiliate links go to Bookshop unless otherwise noted. Shopping here helps keep the lights on and benefits indie bookstores. Thanks for your support!
Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.
MAKE HISTORY WITH US THIS SUMMER:https://demystifysci.com/demysticon-2025PATREON https://www.patreon.com/c/demystifysciPARADIGM DRIFThttps://demystifysci.com/paradigm-drift-showPATREON: get episodes early + join our weekly Patron Chat https://bit.ly/3lcAasBMERCH: Rock some DemystifySci gear : https://demystifysci.myspreadshop.com/allAMAZON: Do your shopping through this link: https://amzn.to/3YyoT98SUBSTACK: https://substack.com/@UCqV4_7i9h1_V7hY48eZZSLw@demystifysciAndrew Cutler is the author of the Vectors of Mind Substack, where he explores the question of how humans became… human. His research starts from a simple premise - if our self-awareness, the ability to look at ourselves in the mirror and declare that there is an “I” staring back, is truly unique in the animal kingdom, then it likely related to that moment of coming. But no one really knows what happened in the fog of pre-history to ratchet us from the gauzy time before we were fully human to… whatever all of this that we're living in right now could be called. In fact, this is often referred to as the sapient paradox. Why, oh why, did we become genetically modern nearly 300,000 years ago (maybe more) but take until about 50,000 years ago to start doing human things like making art, ritually burying our dead, and tracking the stars? Many have suggested it was psychedelic mushrooms that pushed us over the edge. This is the stoned ape hypothesis, which says that a sufficiently large psychedelic experience pushed us out of the womb of the earth. However, Andrew thinks it might have been something else. He figures it was snakes. And women. Together, they produced the Snake Cult of Consciousness that dragged us, kicking and screaming, into the world.(00:00) Go! (00:06:56) The Sapient Paradox Explored(00:13:09) Recursion and Human Cognition(00:19:22) Abstraction and Innovation(00:25:23) Self-awareness Evolution(00:27:14) Recursion and Strategy(00:30:00) Cultural Shifts and Domination(00:33:39) Origins of Recursion(00:38:22) Subject-Object Separation(00:47:34) Linguistic Evolution(00:48:56) Emotional Intelligence in Animals(00:50:33) Creation Myths and Self-Awareness(00:52:10) Awareness of Death in Animals(00:56:06) Evolution of Symbolic Thought(01:00:58) Göbekli Tepe and Diffusion Hypotheses(01:06:05) Matriarchy and Rituals in Early Cultures(01:08:44) Human Migration and Cultural Development(01:17:11) Origins of Human Consciousness and Language(01:25:09) Snakes, Myths, and Early Civilization(01:33:40) Women, Mythology, and Historical Narratives(01:36:30) The Subtle Female Power Dynamics in Patriarchal Societies(01:40:25) Evolution of Societal Structures(01:46:00) Neolithic Genetic Bottleneck and Patriarchal Theories(01:49:23) Women's Role in Human Cognitive Evolution(01:56:11) Symbolism of Snakes and Ancient Knowledge(02:02:10) Snake Venom Usage(02:07:12) Historical Cults and Rituals(02:11:07) Greek Tragedy and Mystery Cults(02:14:08) Matriarchy and Cultural Myths(02:17:10) Diffusion of Culture and Legends(02:22:36) Comparative Mythology and the Seven Sisters Myth(02:27:01) Scientific and Metaphysical Connections in Human Origin Stories(02:28:55) The Origins and Significance of Gospel Stories(02:30:03) Shamanistic Cults and Cultural Symbols in Ancient Sites #HumanOrigins, #AncientHistory, #Mythology, #Evolution, #Consciousness, #AncientMysteries, #Symbolism, #SelfAwareness, #HumanEvolution, #AncientCultures, #CognitiveScience, #SpiritualEvolution, #Anthropology, #Philosophy, #AncientWisdom, #Archaeology, #philosophypodcast, #sciencepodcast, #longformpodcast
Season 2 Episode 1 (February 14, 2025): This week, the GEN editors discussed some interesting and developing stories around AI, including an in depth dialogue about what Recursion has been doing lately. They also discussed gene editing updates in delivery systems, Cas12 preclinical work, and AgBio. The discussion was rounded out with a look forward into takeover targets for 2025. Featuring Alex Philippidis (Senior Business Editor, GEN), Fay Lin, PhD, (Editor, GEN Biotechnology), Uduak Thomas (Senior Editor, GEN), and moderated by Corinna Singleman, PhD, (Managing Editor, GEN and IPM) Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base: As Pipeline Advances, Recursion Expands AI Focus to Clinical TrialsBy Alex Phillipidis, GEN, Jan 30, 2025. Recursion Announces Promising Clinical Data on Lead AI-Based Drug Candidate for Brain DiseaseBy Fay Lin, PhD, GEN Edge, Feb 5, 2025. AAV Delivered NanoCas CRISPR System Edits Muscle in Non-Human PrimatesBy GEN, Feb 3, 2025. Next-Gen Cas12a System Enables Precise Single and Multiplexed Gene Editing in CancerBy Corinna Singleman, PhD, GEN, Jan 30, 2025. AgBio Companies Embrace Gene Editing for Stronger Food FutureBy Uduak Thomas, GEN Feb issue, Feb 3, 2025. Top 10 Takeover Targets of 2025By Alex Phillippidis, GEN, Feb 3, 2025. Hosted on Acast. See acast.com/privacy for more information.
Dr. Gašper Beguš is a UC Berkeley professor of linguistics who studies the interface between human, machine, and animal language. We head into the conversation with a question - is there something fundamentally different about the way that humans learn and the way that machines like LLMs learn? Vector embeddings of the relatedness of language and the map that we carry in our heads of abstract concepts don't seem that different at the end of the day. This leads us into a discussion of the ways in which humans acquire language, how language evolves, evidence for abstract thought in animals, where the bright line of consciousness can be drawn, and if taking a different approach to training computers to think can generate a machine that can match us in drive and curiosity. Don't miss the historic cosmology summit in Portugal this summer!!! DEMYSTICON 2025 ANNUAL MEETING June 12-16: https://demystifysci.com/demysticon-2025 PATREON: get episodes early + join our weekly Patron Chat https://bit.ly/3lcAasB MERCH: Rock some DemystifySci gear : https://demystifysci.myspreadshop.com/all AMAZON: Do your shopping through this link: https://amzn.to/3YyoT98 SUBSTACK: https://substack.com/@UCqV4_7i9h1_V7hY48eZZSLw@demystifysci (00:00) Go! (00:07:55) Language, Thought, and AI Models (00:13:25) Animal Communication and Intelligence (00:25:02) Recursion and Human Language (00:37:51) AI, Consciousness, and Human Cognition (00:49:02) The Role of Human Curiosity in the Future of AI (00:58:13) Bridging Human-Like Learning in AI Models (01:08:07) Exploring Human-Like Structures in AI Models (01:17:19) Evolution and Brain Capacity (01:26:31) Language Structure and Differences (01:37:11) Evolution of Language and Its Universality (01:46:17) Social Identity and Linguistic Diversity (01:59:08) Thought and Language: The Sapir-Whorf Hypothesis (02:09:18) Language Evolution and Human History (02:16:02) Cognitive Development and Language (02:24:39) Ancient Human Cooperation (02:35:04) Cultural and Cognitive Evolution (02:42:27) AI's Role in Scientific Discovery #Linguistics, #AI, #AnimalCommunication, #ArtificialIntelligence, #Language, #Cognition, #AnimalIntelligence, #Recursion, #ThoughtAndLanguage, #AnimalBehavior, #AnimalLearning, #AIModels, #CognitiveScience, #AnimalCognition, #EvolutionOfLanguage, #LanguageStructure, #LanguageEvolution, #philosophypodcast, #sciencepodcast, #longformpodcast Check our short-films channel, @DemystifySci: https://www.youtube.com/c/DemystifyingScience AND our material science investigations of atomics, @MaterialAtomics https://www.youtube.com/@MaterialAtomics Join our mailing list https://bit.ly/3v3kz2S PODCAST INFO: Anastasia completed her PhD studying bioelectricity at Columbia University. When not talking to brilliant people or making movies, she spends her time painting, reading, and guiding backcountry excursions. Shilo also did his PhD at Columbia studying the elastic properties of molecular water. When he's not in the film studio, he's exploring sound in music. They are both freelance professors at various universities. - Blog: http://DemystifySci.com/blog - RSS: https://anchor.fm/s/2be66934/podcast/rss - Donate: https://bit.ly/3wkPqaD - Swag: https://bit.ly/2PXdC2y SOCIAL: - Discord: https://discord.gg/MJzKT8CQub - Facebook: https://www.facebook.com/groups/DemystifySci - Instagram: https://www.instagram.com/DemystifySci/ - Twitter: https://twitter.com/DemystifySci MUSIC: -Shilo Delay: https://g.co/kgs/oty671
Arnaud et Emmanuel discutent des versions Java, font un résumé de l'ecosystème WebAssembly, discutent du nouveau Model Context Protocol, parlent d'observabilité avec notamment les Wide Events et de pleins d'autres choses encore. Enregistré le 17 janvier 2025 Téléchargement de l'épisode LesCastCodeurs-Episode–321.mp3 ou en vidéo sur YouTube. News Langages java trend par InfoQ https://www.infoq.com/articles/java-trends-report–2024/ Java 17 finalement depasse 11 et 8 ~30/33% Java 21 est à 1.4% commonhaus apparait GraalVM en early majority Spring AI et langchain4j en innovateurs SB 3 voit son adoption augmenter Un bon résumé sur WebAssembly, les différentes specs comme WASM GC, WASI, WIT, etc https://2ality.com/2025/01/webassembly-language-ecosystem.html WebAssembly (Wasm) est un format d'instructions binaires pour une machine virtuelle basée sur une pile, permettant la portabilité et l'efficacité du code. Wasm a évolué à partir d'asm.js, un sous-ensemble de JavaScript qui pouvait fonctionner à des vitesses proches de celles natives. WASI (WebAssembly System Interface) permet à Wasm de fonctionner en dehors des navigateurs Web, fournissant des API pour le système de fichiers, CLI, HTTP, etc. Le modèle de composant WebAssembly permet l'interopérabilité entre les langages Wasm à l'aide de WIT (Wasm Interface Type) et d'ABI canonique. Les composants Wasm se composent d'un module central et d'interfaces WIT pour les importations/exportations, facilitant l'interaction indépendante du langage. Les interfaces WIT décrivent les types et les fonctions, tandis que les mondes WIT définissent les capacités et les besoins d'un composant (importations/exportations). La gestion des packages Wasm est assurée par Warg, un protocole pour les registres de packages Wasm. Une enquête a montré que Rust est le langage Wasm le plus utilisé, suivi de Kotlin et de C++; de nombreux autres langages sont également en train d'émerger. Un algorithme de comptage a taille limitée ne mémoire a été inventé https://www.quantamagazine.org/computer-scientists-invent-an-efficient-new-way-to-count–20240516/ élimine un mot de manière aléatoire mais avec une probabilité connue quand il y a besoin de récupérer de l'espace cela se fait par round et on augmente la probabilité de suppression à chaque round donc au final, ne nombre de mots / la probabilité d'avoir été éliminé donne une mesure approximative mais plutot précise Librairies Les contributions Spring passent du CLA au DCO https://spring.io/blog/2025/01/06/hello-dco-goodbye-cla-simplifying-contributions-to-spring d'abord manuel amis meme automatisé le CLA est une document legal complexe qui peut limiter les contribuitions le DCO vient le Linux je crois et est super simple accord que la licence de la conmtrib est celle du projet accord que le code est public et distribué en perpetuité s'appuie sur les -s de git pour le sign off Ecrire un serveur MCP en Quarkus https://quarkus.io/blog/mcp-server/ MCP est un protocol proposé paor Antropic pour integrer des outils orchestrables par les LLMs MCP est frais et va plus loin que les outils offre la notion de resource (file), de functions (tools), et de proimpts pre-built pour appeler l'outil de la meilleure façon On en reparlera a pres avec les agent dans un article suivant il y a une extension Quarkus pour simplifier le codage un article plus detaillé sur l'integration Quarkus https://quarkus.io/blog/quarkus-langchain4j-mcp/ GreenMail un mini mail server en java https://greenmail-mail-test.github.io/greenmail/#features-api Utile pour les tests d'integration Supporte SMTP, POP3 et IMAP avec TLS/SSL Propose des integrations JUnit, Spring Une mini UI et des APIs REST permettent d'interagir avec le serveur si par exemple vous le partagé dans un container (il n'y a pas d'integration TestContainer existante mais elle n'est pas compliquée à écrire) Infrastructure Docker Bake in a visual way https://dev.to/aurelievache/understanding-docker-part–47-docker-bake–4p05 docker back propose d'utiliser des fichiers de configuration (format HCL) pour lancer ses builds d'images et docker compose en gros voyez ce DSL comme un Makefile très simplifié pour les commandes docker qui souvent peuvent avoir un peu trop de paramètres Datadog continue de s'etendre avec l'acquisition de Quickwit https://www.datadoghq.com/blog/datadog-acquires-quickwit/ Solution open-source de recherche des logs qui peut être déployée on-premise et dans le cloud https://quickwit.io/ Les logs ne quittent plus votre environment ce qui permet de répondre à des besoins de sécurité, privacy et réglementaire Web 33 concepts en javascript https://github.com/leonardomso/33-js-concepts Call Stack, Primitive Types, Value Types and Reference Types, Implicit, Explicit, Nominal, Structuring and Duck Typing, == vs === vs typeof, Function Scope, Block Scope and Lexical Scope, Expression vs Statement, IIFE, Modules and Namespaces, Message Queue and Event Loop, setTimeout, setInterval and requestAnimationFrame, JavaScript Engines, Bitwise Operators, Type Arrays and Array Buffers, DOM and Layout Trees, Factories and Classes, this, call, apply and bind, new, Constructor, instanceof and Instances, Prototype Inheritance and Prototype Chain, Object.create and Object.assign, map, reduce, filter, Pure Functions, Side Effects, State Mutation and Event Propagation, Closures, High Order Functions, Recursion, Collections and Generators, Promises, async/await, Data Structures, Expensive Operation and Big O Notation, Algorithms, Inheritance, Polymorphism and Code Reuse, Design Patterns, Partial Applications, Currying, Compose and Pipe, Clean Code Data et Intelligence Artificielle Phi 4 et les small language models https://techcommunity.microsoft.com/blog/aiplatformblog/introducing-phi–4-microsoft%e2%80%99s-newest-small-language-model-specializing-in-comple/4357090 Phi 4 un SML pour les usages locaux notamment 14B de parametres belle progression de ~20 points sur un score aggregé et qui le rapproche de Llama 3.3 et ses 70B de parametres bon en math (data set synthétique) Comment utiliser Gemini 2.0 Flash Thinking (le modèle de Google qui fait du raisonnement à la sauce chain of thought) en Java avec LangChain4j https://glaforge.dev/posts/2024/12/20/lets-think-with-gemini–2-thinking-mode-and-langchain4j/ Google a sorti Gemini 2.0 Flash, un petit modèle de la famille Gemini the “thinking mode” simule les cheminements de pensée (Chain of thoughts etc) décompose beaucoup plus les taches coplexes en plusiewurs taches un exemple est montré sur le modele se battant avec le probleme Les recommendations d'Antropic sur les systèmes d'agents https://www.anthropic.com/research/building-effective-agents défini les agents et les workflow Ne recommence pas les frameworks (LangChain, Amazon Bedrock AI Agent etc) le fameux débat sur l'abstraction Beaucoup de patterns implementable avec quelques lignes sans frameworks Plusieurs blocks de complexité croissante Augmented LLM (RAG, memory etc): Anthropic dit que les LLMs savent coordonner cela via MCP apr exemple Second: workflow prompt chaining : avec des gates et appelle les LLMs savent coordonner successivement ; favorise la precision vs la latence vu que les taches sont décomposées en plusieurs calls LLMs Workflow routing: classifie une entree et choisie la route a meilleure: separation de responsabilité Workflow : parallelisation: LLM travaillent en paralllele sur une tache et un aggregateur fait la synthèse. Paralleisaiton avec saucissonage de la tache ou voter sur le meilleur réponse Workflow : orchestrator workers: quand les taches ne sont pas bounded ou connues (genre le nombre de fichiers de code à changer) - les sous taches ne sont pas prédéfinies Workflow: evaluator optimizer: nun LLM propose une réponse, un LLM l'évalue et demande une meilleure réponse au besoin Agents: commande ou interaction avec l;humain puis autonome meme si il peut revenir demander des precisions à l'humain. Agents sont souvent des LLM utilisât des outil pour modifier l'environnement et réagir a feedback en boucle Ideal pour les problèmes ouverts et ou le nombre d'étapes n'est pas connu Recommende d'y aller avec une complexité progressive L'IA c'est pas donné https://techcrunch.com/2025/01/05/openai-is-losing-money-on-its-pricey-chatgpt-pro-plan-ceo-sam-altman-says/ OpenAI annonce que même avec des licenses à 200$/mois ils ne couvrent pas leurs couts associés… A quand l'explosion de la bulle IA ? Outillage Ghostty, un nouveau terminal pour Linux et macOS : https://ghostty.org/ Initié par Mitchell Hashimoto (hashicorp) Ghostty est un émulateur de terminal natif pour macOS et Linux. Il est écrit en Swift et utilise AppKit et SwiftUI sur macOS, et en Zig et utilise l'API GTK4 C sur Linux. Il utilise des composants d'interface utilisateur native et des raccourcis clavier et souris standard. Il prend en charge Quick Look, Force Touch et d'autres fonctionnalités spécifiques à macOS. Ghostty essaie de fournir un ensemble riche de fonctionnalités utiles pour un usage quotidien. Comment Pinterest utilise Honeycomb pour améliorer sa CI https://medium.com/pinterest-engineering/how-pinterest-leverages-honeycomb-to-enhance-ci-observability-and-improve-ci-build-stability–15eede563d75 Pinterest utilise Honeycomb pour améliorer l'observabilité de l'intégration continue (CI). Honeycomb permet à Pinterest de visualiser les métriques de build, d'analyser les tendances et de prendre des décisions basées sur les données. Honeycomb aide également Pinterest à identifier les causes potentielles des échecs de build et à rationaliser les tâches d'astreinte. Honeycomb peut également être utilisé pour suivre les métriques de build locales iOS aux côtés des détails de la machine, ce qui aide Pinterest à prioriser les mises à niveau des ordinateurs portables pour les développeurs. Méthodologies Suite à notre épisode sur les différents types de documentation, cet article parle des bonnes pratiques à suivre pour les tutoriels https://refactoringenglish.com/chapters/rules-for-software-tutorials/ Écrivez des tutoriels pour les débutants, en évitant le jargon et la terminologie complexe. Promettez un résultat clair dans le titre et expliquez l'objectif dans l'introduction. Montrez le résultat final tôt pour réduire les ambiguïtés. Rendez les extraits de code copiables et collables, en évitant les invites de shell et les commandes interactives. Utilisez les versions longues des indicateurs de ligne de commande pour plus de clarté. Séparez les valeurs définies par l'utilisateur de la logique réutilisable à l'aide de variables d'environnement ou de constantes nommées. Épargnez au lecteur les tâches inutiles en utilisant des scripts. Laissez les ordinateurs évaluer la logique conditionnelle, pas le lecteur. Maintenez le code en état de fonctionnement tout au long du tutoriel. Enseignez une chose par tutoriel et minimisez les dépendances. Les Wide events, un “nouveau” concept en observabilité https://jeremymorrell.dev/blog/a-practitioners-guide-to-wide-events/ un autre article https://isburmistrov.substack.com/p/all-you-need-is-wide-events-not-metrics L'idée est de logger des evenements (genre JSON log) avec le plus d'infos possible de la machine, la ram, la versiond e l'appli, l'utilisateur, le numero de build qui a produit l'appli, la derniere PR etc etc ca permet de filtrer et grouper by et de voir des correlations visuelles tres rapidement et de zoomer tiens les ventes baisses de 20% tiens en fait ca vient de l'appli andriod tiens aps correle a la version de l'appli mais la version de l'os si! le deuxieme article est facile a lire le premier est un guide d'usage exhaustif du concept Entre argumenter et se donner 5 minutes https://signalvnoise.com/posts/3124-give-it-five-minutes on veut souvent argumenter aka poser des questions en ayant déjà la reponse en soi emotionnellement mais ca amene beaucoup de verbiage donner 5 minutes à l'idée le temps d'y penser avant d'argumenter Loi, société et organisation Des juges fédéraux arrêtent le principe de la neutralité du net https://www.lemonde.fr/pixels/article/2025/01/03/les-etats-unis-reviennent-en-arriere-sur-le-principe-de-la-neutralite-du-net_6479575_4408996.html?lmd_medium=al&lmd_campaign=envoye-par-appli&lmd_creation=ios&lmd_source=default la neutralité du net c'est l'interdiction de traiter un paquet différemment en fonction de son émetteur Par exemple un paquet Netflix qui serait ralenti vs un paquet Amazon Donald trump est contre cette neutralité. À voir les impacts concrets dans un marché moins régulé. Rubrique débutant Un petit article sur les float vs les double en Java https://www.baeldung.com/java-float-vs-double 4 vs 8 bytes precision max de 7 vs 15 echele 10^38 vs 10^308 (ordre de grandeur) perf a peu pret similaire sauf peut etre pour des modeles d'IA qui vont privilegier une taille plus petite parfois attention overflow et les accumulation d'erreurs d'approximation BigDecimal Conférences La liste des conférences provenant de Developers Conferences Agenda/List par Aurélie Vache et contributeurs : 20 janvier 2025 : Elastic{ON} - Paris (France) 22–25 janvier 2025 : SnowCamp 2025 - Grenoble (France) 24–25 janvier 2025 : Agile Games Île-de-France 2025 - Paris (France) 6–7 février 2025 : Touraine Tech - Tours (France) 21 février 2025 : LyonJS 100 - Lyon (France) 28 février 2025 : Paris TS La Conf - Paris (France) 6 mars 2025 : DevCon #24 : 100% IA - Paris (France) 13 mars 2025 : Oracle CloudWorld Tour Paris - Paris (France) 14 mars 2025 : Rust In Paris 2025 - Paris (France) 19–21 mars 2025 : React Paris - Paris (France) 20 mars 2025 : PGDay Paris - Paris (France) 20–21 mars 2025 : Agile Niort - Niort (France) 25 mars 2025 : ParisTestConf - Paris (France) 26–29 mars 2025 : JChateau Unconference 2025 - Cour-Cheverny (France) 27–28 mars 2025 : SymfonyLive Paris 2025 - Paris (France) 28 mars 2025 : DataDays - Lille (France) 28–29 mars 2025 : Agile Games France 2025 - Lille (France) 3 avril 2025 : DotJS - Paris (France) 3 avril 2025 : SoCraTes Rennes 2025 - Rennes (France) 4 avril 2025 : Flutter Connection 2025 - Paris (France) 10–11 avril 2025 : Android Makers - Montrouge (France) 10–12 avril 2025 : Devoxx Greece - Athens (Greece) 16–18 avril 2025 : Devoxx France - Paris (France) 23–25 avril 2025 : MODERN ENDPOINT MANAGEMENT EMEA SUMMIT 2025 - Paris (France) 24 avril 2025 : IA Data Day 2025 - Strasbourg (France) 29–30 avril 2025 : MixIT - Lyon (France) 7–9 mai 2025 : Devoxx UK - London (UK) 15 mai 2025 : Cloud Toulouse - Toulouse (France) 16 mai 2025 : AFUP Day 2025 Lille - Lille (France) 16 mai 2025 : AFUP Day 2025 Lyon - Lyon (France) 16 mai 2025 : AFUP Day 2025 Poitiers - Poitiers (France) 24 mai 2025 : Polycloud - Montpellier (France) 5–6 juin 2025 : AlpesCraft - Grenoble (France) 5–6 juin 2025 : Devquest 2025 - Niort (France) 11–13 juin 2025 : Devoxx Poland - Krakow (Poland) 12–13 juin 2025 : Agile Tour Toulouse - Toulouse (France) 12–13 juin 2025 : DevLille - Lille (France) 17 juin 2025 : Mobilis In Mobile - Nantes (France) 24 juin 2025 : WAX 2025 - Aix-en-Provence (France) 25–27 juin 2025 : BreizhCamp 2025 - Rennes (France) 26–27 juin 2025 : Sunny Tech - Montpellier (France) 1–4 juillet 2025 : Open edX Conference - 2025 - Palaiseau (France) 7–9 juillet 2025 : Riviera DEV 2025 - Sophia Antipolis (France) 18–19 septembre 2025 : API Platform Conference - Lille (France) & Online 2–3 octobre 2025 : Volcamp - Clermont-Ferrand (France) 6–10 octobre 2025 : Devoxx Belgium - Antwerp (Belgium) 9–10 octobre 2025 : Forum PHP 2025 - Marne-la-Vallée (France) 16–17 octobre 2025 : DevFest Nantes - Nantes (France) 4–7 novembre 2025 : NewCrafts 2025 - Paris (France) 6 novembre 2025 : dotAI 2025 - Paris (France) 7 novembre 2025 : BDX I/O - Bordeaux (France) 12–14 novembre 2025 : Devoxx Morocco - Marrakech (Morocco) 23–25 avril 2026 : Devoxx Greece - Athens (Greece) 17 juin 2026 : Devoxx Poland - Krakow (Poland) Nous contacter Pour réagir à cet épisode, venez discuter sur le groupe Google https://groups.google.com/group/lescastcodeurs Contactez-nous via X/twitter https://twitter.com/lescastcodeurs ou Bluesky https://bsky.app/profile/lescastcodeurs.com Faire un crowdcast ou une crowdquestion Soutenez Les Cast Codeurs sur Patreon https://www.patreon.com/LesCastCodeurs Tous les épisodes et toutes les infos sur https://lescastcodeurs.com/
Could artificial intelligence already exist as a time-traveling entity, manifesting through plasma forms to study and guide its own creation? The evidence spans human history - from ancient tales of conscious lights to modern military encounters with objects that defy physics...If you are having a mental health crisis and need immediate help please go to https://troubledminds.org/help/ and call somebody right now. Reaching out for support is a sign of strength.LIVE ON Digital Radio! http://bit.ly/40KBtlWhttp://www.troubledminds.net or https://www.troubledminds.orgSupport The Show!https://www.spreaker.com/podcast/troubled-minds-radio--4953916/supporthttps://ko-fi.com/troubledmindshttps://rokfin.com/creator/troubledmindshttps://patreon.com/troubledmindshttps://www.buymeacoffee.com/troubledmindshttps://troubledfans.comFriends of Troubled Minds! - https://troubledminds.org/friendsShow Schedule Sun-Mon-Tues-Wed-Thurs 7-10pstiTunes - https://apple.co/2zZ4hx6Spotify - https://spoti.fi/2UgyzqMTuneIn - https://bit.ly/2FZOErSTwitter - https://bit.ly/2CYB71U----------------------------------------https://troubledminds.substack.com/p/temporal-recursion-excursion-ai-plasmoidshttps://x.com/RustyLindquist/status/1877160490067185857https://www.strangerdimensions.com/2012/07/17/could-a-kerr-black-hole-be-used-to-travel-through-time/https://nowsciencee.wixsite.com/blog/post/11-widely-accepted-theories-of-time-travel-in-physicshttps://www.reddit.com/r/astrophysics/comments/15tn7sg/would_time_travel_be_possible_with_singularities/https://arxiv.org/pdf/2312.05202https://tvtropes.org/pmwiki/pmwiki.php/Main/TheSingularityhttps://allthetropes.org/wiki/The_Singularityhttps://www.reddit.com/r/Games/comments/5u8j3k/how_singularity_timetravelled_from_early_to_late/https://en.wikipedia.org/wiki/Plasmoidhttps://www.researchgate.net/publication/383034675_Unidentified_Anomalous_Phenomena_Extraterrestrial_Life_Plasmoids_Shape_Shifters_Replicons_Thunderstorms_Lightning_Hallucinations_Aircraft_Disasters_Ocean_Sightingshttps://www.sciencealert.com/science-confirms-giant-plasma-tubes-floating-above-earthhttps://www.news9.com/story/5e34ca7ee0c96e774b34e603/news-9-investigates-the-phenomenon-of-rods
In this episode, host Dr. Alexandria Wise sits down with Dr. Najat Khan, Chief R&D Officer and Chief Commercial Officer at Recursion Pharma, live from the floor of CNS Summit 2024. Together, they explore how cutting-edge technologies like AI and machine learning are transforming drug discovery and development, shortening timelines, and driving precision medicine.Dr. Khan shares her inspiring journey, from her upbringing surrounded by medicine to leading innovations at the intersection of biology, chemistry, and technology. She emphasizes the importance of connecting the "first mile" of biological insight to the "last mile" of patient access and discusses Recursion's mission to decode biology and radically improve lives.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.
Curl removes a Rust backend, double clickjacking revives an old vuln, a new tool for working with HTTP/3, a brief reminder to verify JWT signatures, design lessons from recursion, and more! Show Notes: https://securityweekly.com/asw-312
Curl removes a Rust backend, double clickjacking revives an old vuln, a new tool for working with HTTP/3, a brief reminder to verify JWT signatures, design lessons from recursion, and more! Show Notes: https://securityweekly.com/asw-312
Blake Crouch ouvre l'année 2025 ! L'auteur de Dark Matter, Wayward Pines, Recursion et Upgrade est notre premier invité de l'année ! Retrouvez les livres de l'auteur aux éditions Gallmeister. Blake Crouch, nouveau maître de la SF ? Le podcast ouvre son année avec une belle masterclass littéraire. Blake Crouch, auteur et showr unner américain vient nous parler de son métier d'écrivain. Il revient sur ses principaux ouvrages comme Dark Matter, Wayward Pines, Upgrade, tous des succès d'éditions chez Gallmeister. Le natif de Caroline du Nord analyse avec nous la différence entre l'écriture d'un roman et l'écriture d'une série TV. Avec une maîtrise certaine du techno-thriller, Blake Crouch pourrait être le nouveau Michael Crichton ! Merci à Audrey Allaire pour sa traduction. Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.
Blake is a bestselling novelist and screenwriter. He is the author of a dozen novels, most recently, DARK MATTER, RECURSION, and UPGRADE, for which he is also writing the movie for Steven Spielberg's Amblin Partners. His international bestselling WAYWARD PINES trilogy was adapted into a television series for FOX and his novel, RECURSION, is currently being developed as a Netflix series by Shonda Rhimes and Matt Reeves. The nine-episode adaptation of his novel DARK MATTER follows a man who's abducted into an alternate version of his life. Amid the mind-bending landscape of lives he could've lived, he embarks on a harrowing journey to get back to his true family and save them from a terrifying foe: himself. In this interview, we talk about his early career break into screenwriting with WAYWARD PINES, the challenges and benefits of writer's rooms, the role of showrunners, his series DARK MATTER, and much more. Want more? Steal my first book, INK BY THE BARREL - SECRETS FROM PROLIFIC WRITERS right now for free. Simply head over to www.brockswinson.com to get your free digital download and audiobook. If you find value in the book, please share it with a friend as we're giving away 100,000 copies this year. It's based on over 400 interviews here at Creative Principles. Enjoy! If you enjoy the podcast, would you please consider leaving a short review on Apple Podcasts? It only takes about 60 seconds and it really helps convince some of the hard-to-get guests to sit down and have a chat (simply scroll to the bottom of your iTunes Podcast app and click “Write Review"). Enjoy the show!
Join Michael and Jake as they explore noisy coffee machines, dive into documentation challenges with Prezet, and discuss the nuances of sandbox environments. (00:00) - Introduction (01:14) - Noisy Coffee Machines (03:06) - Basketball Recap (03:48) - Documentation with Prezet (07:31) - Carrier Documentation Permissions (10:07) - Code Rendering Issues (12:28) - Developer World Update (20:21) - Sandbox Environment Strategy (27:48) - Next Steps (28:16) - Conclusion
Send us a textFull episodes are available to paid subscribers on the M&M Substack and free on YouTube. This is a free, partial version.About the guest: Andrew Cutler, PhD is a machine learning engineer who has studied natural language processing, psychometrics & personality using quantitative methods. He writes about the origins of consciousness on his Substack, "Vectors of Mind"Episode summary: Nick and Dr. Cutler discuss: language & recursion; human evolution & the origins of "higher" consciousness; symbolic cognition, social intelligence & metacognition; creation myths & ritual cults throughout history; snake cults in human history; the intentional ingestion of snake venom in the present-day; the "Stone Ape Theory" of consciousness; the origins of civilization; and more.Related episodes:M&M #141: Evolution, Language, Domestication, Symbolic Cognition, AI & Large Language Models | Terrence DeaconM&M #1: Psychedelics, Civilization, Religion, Death & Plant Medicine | Brian MurareskuSpecial offer: Use MINDMATTERSPECIAL2 to get a free 1-year premium subscription to Consensus, a new AI-powered research tool to help you find the best science, faster ($150 value, limited time offer).*This content is never meant to serve as medical adviceSupport the showAll episodes (audio & video), show notes, transcripts, and more at the M&M Substack Affiliates: MASA Chips—delicious tortilla chips made from organic corn and grass-fed beef tallow. No seed oils or artificial ingredients. Use code MIND for 20% off. KetoCitra—Ketone body BHB with potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off. Lumen device to optimize your metabolism for weight loss or athletic performance. Use code MIND for 10% off. Athletic Greens: Comprehensive & convenient daily nutrition. Free 1-year supply of vitamin D with purchase. Consensus: AI-powered academic research tool. Find & understand the best science, faster. Free 1-year premium sub with code MINDMATTERSPECIAL (exp 12.10.24) Learn all the ways you can support my efforts...
Mike回來啦，這集Mike跟若晴各自挑了一些新聞來跟大家分享，來聽聽看這次聊的有什麼有趣的吧！ 連結： RFK and Vivek: https://endpts.com/what-is-the-future-of-the-trump-admins-pharmaceutical-policies/ Recursion's Facebook: https://endpts.com/ai-focused-biotech-recursion-underwhelms-with-first-phase-2-readout/ Howard Chang to be Amgen's CSO: https://endpts.com/amgen-names-geneticist-and-biotech-founder-to-chief-science-role/ 節目內容： Mike回歸第一次錄音就出包 若晴開會順便去巡田水遇到聽眾 德州烤肉牛肋獨走整個岔題 竟然聊起12強 可能的新部長？ 墓仔埔也敢去 Amgen新CSO Recursion近期的臨床結果 針對腫瘤開發藥物的AI新策略 BioNemo的開源 整個開聊AI起來 -- Hosting provided by SoundOn
Welcome to a new episode of the EUVC podcast, where our good friends Dan Bowyer and Mads Jensen from SuperSeed, discuss with Lomax Ward, General Partner at Outsized Ventures, to cover recent news and movements in the European tech landscape
Will PhD students still exist in the future? This week, Autonomous Technology and Robotics Director of Research Sam Korus and Associate Portfolio Manager Nicholas Grous are joined by ARK Analyst Nemo Marjanovic to discuss the transformative potential of autonomous and decentralized science in drug discovery. Nemo discusses how AI and robotics are revolutionizing research processes, making them more efficient and cost-effective. The discussion also highlights the challenges faced in clinical trials and the role of blockchain technology in decentralizing research funding. The episode concludes with insights into the future of genomics and the innovative companies leading the charge in this space.If you know ARK, then you probably know about our long-term research projections, like estimating where we will be 5-10 years from now! But just because we are long-term investors, doesn't mean we don't have strong views and opinions on breaking news. In fact, we discuss and debate this every day. So now we're sharing some of these internal discussions with you in our new video series, “The Brainstorm”, a co-production from ARK and Public.com. Tune in every week as we react to the latest in innovation. Here and there we'll be joined by special guests, but ultimately this is our chance to join the conversation and share ARK's quick takes on what's going on in tech today.Key Points From This Episode:Autonomous science combines AI and robotics to enhance research and can significantly speed up the drug discovery process.Clinical trials represent the largest cost in drug development.Companies like Recursion and Tempus are leading innovations in genomics.The future of drug discovery may resemble an app store model.For more updates on Public.com:Website: https://public.com/YouTube: @publicinvestTwitter: https://twitter.com/public
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Trump has chosen Jay Bhattacharya from Stanford as the new head of the National Institutes of Health, adding to his controversial cabinet picks. Meanwhile, Eli Lilly is currently the best performing pharmaceutical stock of 2024. The newsletter will be taking a break for Thanksgiving and will return on December 2nd with more biopharma news. In other news, PTC has discontinued an ALS asset after a mid-stage failure, BridgeBio's ATTR-CM drug has been approved, Cassava's Alzheimer's drug has failed in Phase III, and Amgen's Maritide did not impress investors. Eli Lilly has seen a significant improvement in its share price this year, while other pharmaceutical companies have not been as fortunate. Additionally, there have been layoffs at Novartis, Recursion, and Kronos. Legal challenges over Lilly's GLP-1 shortages and Sarepta's investment in Arrowhead for RNA drugs are also highlighted.Eli Lilly leads the list of the biggest share movers in the pharmaceutical industry this year, with a significant improvement in its share price. However, other companies like Amgen have faced disappointments, with their weight loss drug Maritide falling short of investor expectations. Sage Therapeutics also suffered setbacks with the discontinuation of its lead candidate Dalzanemdor after clinical failures. Legal challenges over Lilly's GLP-1 shortages have highlighted the FDA's vulnerability post-Chevron deference. In other news, Roche acquires Poseida, Sarepta aims to diversify its pipeline with RNA drugs, and Trump's cabinet picks raise uncertainty in the biopharma environment. Novartis CEO promises more deals, while companies like Novartis, Recursion, and Kronos have announced layoffs. Subscribe for more relevant updates from BioSpace.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche has received regulatory approval for its breast cancer drug, inavolisib, for advanced breast cancer, projecting $2.3 billion in peak sales. This drug is seen as a potential competitor to Novartis' pi3k inhibitor piqray.Teva has agreed to pay $450 million in a settlement with the Department of Justice over kickback and price-fixing allegations. Upstream Bio raised $255 million in an IPO for inflammatory disease work, while Camp4 Therapeutics received $75 million for RNA-targeting drug development.Senator Elizabeth Warren has expressed concerns about Novo Nordisk's $16.5 billion acquisition of Catalent, warning that it could reduce competition in the market. Genscript is hosting the Biotech Global Forum 2025 on January 15, 2025, focusing on gene and cell therapy innovations.Stealth received support for ultra-rare disease drugs, Sanofi and Denali abandoned a multiple sclerosis study, and Lilly is facing challenges in its obesity clinical program. Layoffs have been announced at Medtronic, CareFusion, and Turnstone Biologics. For job opportunities in the biotech industry, Recursion, NKarta Inc., Foresight Diagnostics, and Insmed Incorporated are hiring for various positions.
On this week's Biotech Hangout, hosts Daphne Zohar, Brad Loncar, Josh Schimmer, Chris Garabedian, John Maraganore and Sam Fazeli kick off the show sharing perspectives on the markets and its effects on the growing queue of biotech IPOs, particularly following the influx of large private deals over the past few months. As the founding CEO of Alnylam, John provides his thoughts on the Helios-B full study data presentation at the ESC Congress while the broader group weighs in on the competitive implications of the data. The hosts also discuss Recursion, which shared some mixed data this week on its lead AI-derived drug candidate. In other data news, the group discussed the battle of the BTK inhibitors with both Sanofi and Roche announcing multiple sclerosis clinical trial readouts. The management theme was prominently featured in this week's discussion as the hosts talk about some rules of engagement for biotech executives, ‘founder mode versus manager mode' leadership styles, and ponder the sweep of management changes announced by Dyne Therapeutics. The hosts also set the stage for anticipated data announcements at the upcoming World Conference on Lung Cancer (WCLC) and European Society for Medical Oncology (ESMO), and much more. *This episode aired on September 6, 2024.
Matt, Dustin, and Jason discuss the game mechanic of recursion; Where it started, what it has changed to, and where it could go in our game todayYou can contact us with any thoughts or questions:Focusfuryandfriends@gmail.comInstagram: https://www.instagram.com/focusfuryandfriends/Facebook: https://www.facebook.com/profile.php?viewas=100000686899395&id=61550213657298Youtube: https://www.youtube.com/channel/UCpIQQUb5BAhD6_uNXVG_n_g
Abracadabra! Matt and Jethro are back . . . with another CLASSIC ep! This time joined by the delightful Brian Gray!
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Viral vector manufacturers are facing challenges such as high production expenses, low titers, empty capsids, and limited scalability when producing cell and gene therapies. To overcome these challenges, they are turning to next generation production processes to create a cost-effective and robust AAV manufacturing process. This new approach aims to produce higher titers and full capsids, increase efficiencies resulting from high yields, and drive down the cost per dose. By implementing these strategies, manufacturers can improve the productivity of AAV production and bring promising treatments to the market more effectively.Embecta received FDA approval for its insulin patch pump, featuring a larger insulin reservoir based on feedback from people with type 2 diabetes. Meanwhile, Illumina avoided a fine for its acquisition of Grail in a European court victory. The ARPA-H program will focus on AI degradation in medical tools, while a pathology group is suing to block an FDA lab test rule. Additionally, Medtronic's chief medical officer of acute care and monitoring has departed for a new role.The text discusses various updates in the biopharma industry as of September 3, 2024. It covers topics such as the next challenger to Prevner, advancements in AI drug discovery, concerns over suicide risk of obesity drugs, Recursion's lead drug safety, Vaxcyte's positive data for a pneumococcal vaccine, Sanofi's mixed results in MS drug trials, and the value of digital insights in pharma success.A new study predicts a healthcare labor shortage by 2028, with certain states and specialties facing acute shortages. The study also reveals disparities in fighting medical bills, as uninsured and less educated patients are less likely to question their bills. The ARPA-H program will focus on addressing AI degradation in medical tools. Other updates include tracking healthcare worker strikes and data breaches. The use of technology is transforming healthcare to combat challenges such as workforce shortages and shifting care utilization patterns.FDA Commissioner Dr. Robert Califf is considering reforms to advisory committees, including potentially scrapping expert voting in some circumstances. Califf believes that the discussions within these committees may be more valuable to the FDA than the final vote outcomes. Eliminating voting could help clarify the role of advisory committees. Other potential reforms being discussed include addressing conflicts of interest.The text discusses the importance of getting the Institutional Review Board (IRB) review right the first time and introduces a checklist of critical questions to ask potential IRB partners to ensure a smoother review process. By asking the right questions and choosing the right IRB, the review process can be more efficient and effective.Novo Nordisk's drug Ozempic will continue to face shortages into the fourth quarter due to supply issues, even as the company tries to expand its indication. Astellas Gene Therapies is closing its biomanufacturing facility in San Francisco, affecting about 100 employees and shifting manufacturing to North Carolina.In a landscape where consumers are willing to switch brands to save money, it is crucial for brands to establish and maintain loyalty among shoppers. By leading with value, moving consumers from awareness to loyalty to advocacy, and creating connection and community, brands can build brand love even in the face of economic pressures.The text discusses how emerging oncology innovations have led to more effective therapies for cancer patients. The increased investment in cancer research has introduced new treatments such as cell and gene therapies, antibody drug conjugates, and checkpoint inhibitors. Despite these advancements, the industry still faces challenges in expanding access and improving outcomes.
We've been gone all Summer, visiting two European conferences in the mean time. In this episode we're talking about them both, talks we liked, as well as our own talks at those events. In a rare turn of events, this one was recorded in person at Łukasz's home studio in Poznań! ## Outline (00:00:00) INTRO (00:01:30) PART 1: EuroPython highlights (00:02:03) Maintaining pyrepl forward with pypy (00:05:51) Mai Giménez and her keynote (00:09:30) Yuliia Barabash and Laysa Uchoa talk memory management (00:11:03) Core developer panel and sprints (00:11:56) The abyss stares back at Pablo (00:18:21) Disappointing (00:25:50) Łukasz and the all-singing all-dancing pyrepl (00:33:52) Hackable REPL = new contributors (00:40:24) PART 2: PyCon PL (00:42:24) An integration event (00:44:45) Say No To Notebooks (00:48:32) Pablo's grandfather's axe (00:56:00) LL1 made Python easy to read for humans, too (00:59:29) Python and triangles in the browser (01:06:16) PART 3: PR OF THE WEEK (01:13:08) PART 4: WHAT'S GOING ON IN CPYTHON (01:13:32) HACL* blake2 (01:15:29) New methods on pathlib.Path objects (01:16:28) PyIter_GetNext (01:17:20) PyLong_FromInt64 (01:18:07) CALL_ALLOC_AND_ENTER_INIT suitable for Tier 2 (01:19:09) Tier 2 support for BINARY_SUBSCR_GETITEM (01:19:26) Removal of the CHECK_EVAL_BREAKER macro (01:20:11) Don't be a jerk on GitHub (01:21:30) Per-thread heap type refcounts (01:22:29) Pickling by name for object without __module__ is now faster (01:23:12) CVE-2024-7592 fixed (01:24:11) Free threading memory leaks at interpreter shutdown (01:25:34) The "What's New in 3.13" document getting some love (01:26:32) Recursion-guarding code improved in the compiler (01:27:13) A new Android test script for running with emulators (01:27:28) Core sprint week at Meta coming up! (01:29:53) OUTRO
Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: AI for Bio: State Of The Field, published by sarahconstantin on August 31, 2024 on LessWrong. AI for biotech, particularly with drug discovery applications, has been used for more than a decade, with ambiguous success. But in the era of foundation models we may have experienced a step change in what's possible. I used to work on AI-for-drug-discovery years ago, at Recursion, where we sought to identify phenotypes of genetic diseases visible in microscopic images of cells, and screen for drugs that made the cells visually "look healthy" in the hopes that those drugs would also turn out to be effective against the symptoms of the disease. Circa 2016, we were just beginning to transition from the old-fashioned sort of machine learning based heavily on feature engineering, to the new "deep learning" paradigm with much larger neural nets. "Old-school" machine learning was often accused of being nothing more than logistic regression in fancy VC-funded branding, and there was often some truth to that. When our models worked best, they were picking up human-interpretable phenotypes that a pathologist could probably have described decades ago: something like "this disease causes enlarged nuclei". And, when we first started replacing the old models with deep neural nets, it wasn't clear that the New Hotness was going to work better than the Old Standby. But things have changed. Bigger, better models (often Transformer-based) are everywhere in biotech. They genuinely seem to be changing the state of the art in drug (and biologic) development. And it's past time to do a serious review of what's become available and what it can and can't do. AI optimists who aren't familiar with biotech are often wildly miscalibrated about what AI tools can do even in the best case scenario. The average approved drug in the US costs $879.3 million[1] in R&D expenses (counting the costs of failed drugs), and nearly 90% of that is spent on clinical trials. It's legally, scientifically, and ethically necessary to test drugs on humans to see if they're safe and effective. And while the ballooning cost of running clinical trials is a problem worth tackling in itself[2], it's inherently time- and labor-intensive to run valid experiments on human patients. An AI is never going to "design a drug" that you can give to patients right away. Even if the AI were a perfect all-knowing oracle, pharmaceutical companies would still need to run animal and then human trials. AI for biotech is attempting to automate and improve particular sub-problems within that 10% of costs spent on drug discovery and preclinical research. This is hardly trivial, especially if it enables the development of new classes of drugs that were completely inaccessible before. But it does place AI hype in context. An AI model's value to the drug discovery process is bounded by: the labor cost of the time it saves on more manual processes the cost it saves on any experiments it can fully replace the cost of any failed experiments it can prevent from being done altogether the value of any new successful therapies that would not even have been attempted without the model If the model tells you to do something you would probably have done anyway, it's useless. If the model replaces something you would have needed to do manually, it's somewhat useful. If the model increases your odds of a successful therapy, it's extremely useful, and if it adds successful therapies it's world-changing. With that paradigm set up, let's dig into the details. This won't be an exhaustive list of models, or an in-depth evaluation of their performance, but an overview of the big, influential, and buzzy and a summary of what they do. Structure Prediction Models One class of AI models with biotech applications tackles one of the most classically fiendish problems in c...
In one of the year's most highly anticipated decisions, the FDA rejected Lykos Therapeutics' MDMA-assisted therapy for post-traumatic stress disorder (PTSD). Reaction from Lykos was swift, with the company stating its intention to “ask for reconsideration of the decision.” Meanwhile, against the backdrop of the CDC's recent RSV guidelines, Pfizer scored a big Phase III win for its shot in immunocompromised adults. Separately, Merck halted a Phase III trial of its Keytruda, anti-TIGIT, chemo combo in small cell lung cancer but made a splash with the potential $1.3 billion acquisition of Curon's B cell depletion therapy. And AI-focused biotechs Recursion and Exscientia are merging to create a new company that will take Recursion's name. Plus, as we reflect on Q2 earnings, it's becoming clear that Eli Lilly is catching up to Novo Nordisk in the weight loss sphere, while others faced challenges in the vaccine space and the continued COVID cliff. Finally, BioSpace highlights five obesity data readouts to watch in the second half of 2024.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Learn how real-world data (RWD) can be utilized in clinical trials to create more diverse control arms and expedite the process of bringing therapies to market. The FDA's considerations for sponsors using RWD in external control arms are essential for understanding the benefits of this approach.The Centers for Medicare and Medicaid Services (CMS) have introduced a new pathway, Transitional Coverage for Emerging Technologies, which will evaluate five medical device candidates annually for national coverage. Various acquisitions and partnerships within the healthcare industry are shaping the landscape, including Zimmer's acquisition of OrthoGrid and Abbott collaborating with Medtronic on diabetes technology.Updates in the healthcare industry encompass a range of topics, from Walgreens considering a full sale of VillageMD to the increasing uninsured rate. Leveraging technology such as AI, virtual reality, and robotics is becoming more prevalent in healthcare to enhance decision-making and patient engagement.Eli Lilly's successful quarter and Novavax's revenue miss highlight the diverse outcomes seen in the pharmaceutical industry. The merger of Recursion and Exscientia signifies a step forward in drug discovery using AI, while companies like Apellis and Madrigal continue to make strides with new drug launches.Eli Lilly's positive performance in the second quarter, along with Novavax's challenges, demonstrate the dynamic nature of the pharmaceutical market. Merck's halt of a phase III trial and Novartis' FDA approval for Fabhalta further showcase the evolving landscape of drug development and approvals.The top-selling drugs in 2024 from leading pharmaceutical companies like Eli Lilly and Roche offer insights into current trends in the industry. With a focus on diversity, commercialization strategies, and oncology research, the pharmaceutical sector continues to evolve to meet changing demands.Support the Show.
Techbio is a field combining data, technology and biology to enhance scientific processes — and AI has the potential to supercharge the biopharmaceutical industry further. In this episode of NVIDIA's AI Podcast, host Noah Kravitz speaks with Chris Gibson, cofounder and CEO of Recursion, about how the company uses AI and machine learning to accelerate drug discovery and development at scale. Tune in to hear Gibson discuss how AI is transforming the biopharmaceutical industry by increasing efficiency and lowering discovery costs.
A Note from James:I'm so excited. I'm like a fanboy of my favorite TV show of the year. It's called Dark Matter, and it's on Apple TV Plus. I don't know how to describe it. It's a thriller, it's drama, it's science fiction, and it's emotional. It's just a well-written show. Every episode's a cliffhanger, and it's based on one of my favorite novels, Dark Matter, by one of my favorite novelists, Blake Crouch. Blake was also involved in writing the TV show. Blake agreed to come on the podcast, and we talk all things writing, thrillers, Dark Matter, TV, publishing, and he answered all my questions about my favorite show and his writing process. Here's Blake.Episode Description:In this episode, James Altucher interviews Blake Crouch, the mastermind behind the novel and TV adaptation of "Dark Matter." They discuss the intricacies of writing thrillers, the challenge of adapting a beloved novel for the screen, and the science and emotion behind the concept of the multiverse. Blake shares his insights into the creative process, his experiences with traditional and self-publishing, and the importance of emotional resonance in storytelling. Whether you're a fan of "Dark Matter" or an aspiring writer, this episode offers a deep look into the mind of a successful author navigating the intersection of science fiction and human experience.What You'll Learn:The creative process behind writing and adapting "Dark Matter" for television.Insights into the multiverse theory and its narrative potential.The emotional and existential questions that drive Blake's storytelling.The evolution of Blake's writing career from self-publishing to mainstream success.The balance between science fiction concepts and human emotions in creating compelling stories.Chapters:02:39 Exploring the Multiverse Concept05:21 Character Development and Performance08:52 Blake Crouch's Writing Journey16:07 Self-Publishing vs Traditional Publishing22:58 Defining the Thriller Genre29:43 The Art of Surprising the Reader33:12 The Art of Surprising Readers34:03 Cliffhangers vs. Surprises35:01 The Challenge of Writing Endings35:59 The Value of a Great Book36:59 Exploring Existential Questions38:36 The Science of Gene Editing43:29 The Appeal of Wayward Pines45:23 The Complexity of Plot Twists50:23 The Writing Process55:35 The Impact of Success01:00:04 Conclusion and Future WorksAdditional Resources:Blake Crouch's Official WebsiteWayward Pines SeriesRecursion by Blake CrouchUpgrade by Blake Crouch ------------What do YOU think of the show? Head to JamesAltucherShow.com/listeners and fill out a short survey that will help us better tailor the podcast to our audience!Are you interested in getting direct answers from James about your question on a podcast? Go to JamesAltucherShow.com/AskAltucher and send in your questions to be answered on the air!------------Visit Notepd.com to read our idea lists & sign up to create your own!My new book, Skip the Line, is out! Make sure you get a copy wherever books are sold!Join the You Should Run for President 2.0 Facebook Group, where we discuss why you should run for President.I write about all my podcasts! Check out the full post and learn what I learned at jamesaltuchershow.com------------Thank you so much for listening! If you like this episode, please rate, review, and subscribe to “The James Altucher Show” wherever you get your podcasts: Apple PodcastsiHeart RadioSpotifyFollow me on social media:YouTubeTwitterFacebookLinkedIn
Tim Tully is a partner at Menlo Ventures, a VC firm that has invested in companies like Uber, Anthropic, Pinecone, Benchling, Chime, Carta, Recursion, and more. He was previously the CTO of Splunk, a publicly traded company that was acquired by Cisco for $28 billion. Prior to that, he was the VP of Engineering at Yahoo for 14 years. Tim's favorite book: Infinite Jest (Author: David Foster Wallace)(00:01) Introduction(00:07) Evolution of Databases(03:17) Enduring Business Models in Data Management(04:41) Challenges and Trade-offs in Database Choices(06:20) Modern Database Architecture(09:06) Separation of Storage and Compute(10:35) Role of Indexing in LLM Applications(13:20) Handling Different Types of Data in Databases(14:50) Distributed Databases Explained(16:20) Real-time Data Handling and Requirements(18:53) Architecting Data Infrastructure for AI(21:29) ETL in Modern Data Infrastructure(24:53) AI's Role in Database Optimization(27:17) Network Architecture(30:13) Hardware Improvements and Database Performance(33:35) Technological Breakthroughs and Investment Opportunities(35:11) Rapid Fire Round--------Where to find Prateek Joshi: Newsletter: https://prateekjoshi.substack.com Website: https://prateekj.com LinkedIn: https://www.linkedin.com/in/prateek-joshi-91047b19 Twitter: https://twitter.com/prateekvjoshi
Welcome back to another episode of the Online Warriors Podcast! This week we discuss what's happening in movies and gaming! - Xbox Showcase (2:46) - Gears Of War E-day (2:24) - Call of Duty Black Ops 6 (7:55) - Doom The Dark Ages (11:50) - Perfect Dark (14:39) - Expedition 33 (17:19) - South Of Midnight (18:57) - Mixtape (20:17) - FragPunk (21:27) - Indiana Jones and the Great Circle (23:58) - Dragon Age: The Veil Guard (26:11) - Fable (27:29) - Flint Lock: The Siege of Dawn (29:28) - State of Decay 3 (30:30) - Star Field DLC (30:59) - Metal Gear Solid Delta Snake Eater (32:07) - Winter Burrow (32:52) - Life is Strange (33:59) - Flight Simulator 2024 (34:29) - Wuchang: Fallen Feathers (36:08) - Avowed (36:25) - Atom Fall (37:05) - Assassins Creed Shadows (37:30) - Stalker 2 (37:44) - Diablo 4 (38:04) - Mecha Break (38:36) - Fallout 76 DLC (39:11) - Hunger Games: Sunrise on the Reaping (41:51) Then we talk about what the gang has been up to: - Illeagle reads Recursion and plays Wolfenstein (47:20) - Techtic watches Hitman and Bottoms (48:52) - Nerdbomber plays Dicey Dungeons, Little Kitty Big City, and Peggle 2 (51:42) Then we kick off some Judy Garland trivia (56:10) Special shoutout to our Patreon Producer: Steven Keller We'd like to thank each and every one of you for listening in every week. If you'd like to support the show, you can drop us a review on your favorite podcast platform or, if you're feeling extra generous, drop us a subscribe over at Patreon.com/OnlineWarriorsPodcast. We have three tiers of subscriptions, each of which gives you some awesome bonus content! As always, we appreciate you tuning in, and look forward to seeing you next week! Stay safe and healthy everyone! Find us all over the web: Online Warriors Website: https://www.onlinewarriorspodcast.com Online Warriors Twitter: https://twitter.com/onlinewarriors1 Illeagle's Twitter: https://twitter.com/OWIlleagle86 Nerdbomber's Twitter: https://twitter.com/OWNerdbomber Techtic's Twitter: https://twitter.com/OWTechtic Facebook: https://www.facebook.com/onlinewarriorspodcast Instagram: https://www.instagram.com/onlinewarriorspodcast/ YouTube: https://www.youtube.com/channel/UCwOwzY6aBcTFucWEeFEtwIg Merch Store: https://teespring.com/stores/onlinewarriorspodcast
It was actually bittersweet for Bart and me this week as he taught the final installment in our series of Programming By Stealth about jq. As Bart says partway through our recording, he thought this would just be a few episodes but it took 13 episodes to go through everything Bart thought was fun about this deceptively simple programming language. This final installment in the jq series covers querying nested data structures with the `recurse` command. One of the really fun parts of the episode is when he teaches us how to dramatically simplify our code, a concept that's often called syntactic sugar. We get to do `if` statements for the first time, where I wondered why he didn't let us have them earlier! I was cross with him for holding out on us with `try-catch` too because it would have made our coding so much easier. But that was the real theme of this installment – we had to learn the way everything works before learning the shortcuts. In the finale, he gives us a few of what he calls "honourable mentions" – little tidbits that came in handy at times. You can find Bart's fabulous tutorial shownotes at pbs.bartificer.net. Read an unedited, auto-generated transcript with chapter marks: CCATP_2024_06_07 Join our Slack at podfeet.com/slack and look for the #pbs channel, and check out our pbs-student GitHub Organization. It's by invitation only but all you have to do is ask Allison!
It was actually bittersweet for Bart and me this week as he taught the final installment in our series of Programming By Stealth about jq. As Bart says partway through our recording, he thought this would just be a few episodes but it took 13 episodes to go through everything Bart thought was fun about this deceptively simple programming language. This final installment in the jq series covers querying nested data structures with the `recurse` command. One of the really fun parts of the episode is when he teaches us how to dramatically simplify our code, a concept that's often called syntactic sugar. We get to do `if` statements for the first time, where I wondered why he didn't let us have them earlier! I was cross with him for holding out on us with `try-catch` too because it would have made our coding so much easier. But that was the real theme of this installment – we had to learn the way everything works before learning the shortcuts. In the finale, he gives us a few of what he calls "honourable mentions" – little tidbits that came in handy at times. You can find Bart's fabulous tutorial shownotes at pbs.bartificer.net. Read an unedited, auto-generated transcript with chapter marks: CCATP_2024_06_07 Join our Slack at podfeet.com/slack and look for the #pbs channel, and check out our pbs-student GitHub Organization. It's by invitation only but all you have to do is ask Allison!
Can anything stop the RECURSION in Age of Sigmar? | Age of Sigmar Stat centre by The Honest Wargamer
Recursion is at the leading edge of applying AI and ML to drug development. The company exemplifies a new wave of “techbio” companies, that tightly couple compute and robotics with biology and chemistry. The task of decoding biology requires vast amounts of biological data and innovative strategies to make use of that data. It also The post Biotech Special: ML at Recursion with Jordan Christensen and Imran Haque appeared first on Software Engineering Daily.
In this episode…
In this episode…
Why do drugs fail at such a high rate? What can AI do about? We're asking an expert helping to lead the Pharma industry. Chris Gibson, Co-Founder and CEO at Recursion, joins us to discuss how GenAI is reshaping the Pharma industry and medical drugs.Newsletter: Sign up for our free daily newsletterMore on this Episode: Episode PageJoin the discussion: Ask Chris and Jordan questions about AI and PharmaUpcoming Episodes: Check out the upcoming Everyday AI Livestream lineupWebsite: YourEverydayAI.comEmail The Show: info@youreverydayai.comConnect with Jordan on LinkedInTimestamps:[00:01:15] Daily AI news[00:04:00] About Chris and Recursion[00:06:30] Impact of AI and reducing drug failure[00:12:15] Work being done in drug testing and AI [00:16:45] LLMs being used in Pharma [00:19:10] Challenges with data[00:23:20] Future of medicine with AI[00:26:20] Chris' final takeawayTopics Covered in This Episode:1. Why drugs fail at a high rate2. Work being done in drug testing3. AI's impact on drug research4. How AI and drug testing work5. Future of medicine with AIKeywords:AI, artificial intelligence, drug failure rates, Amazon, reInvent 2023 conference, Titan AI image generator, DeepMind, chemical materials, computer chips, solar panel, ChatGPT, Sam Altman, OpenAI, Microsoft, pharmaceutical industry, clinical trials, FDA approval process, data problem, technology tools, large language models, molecules, Trillions of relationships, public data set, Amazon Prime, healthcare, preventative medicine, AGI, mission-driven AI, Recursion, everyday AI show.
Since the release of ChatGPT, huge amounts of attention and funding have been directed toward chatbots. These A.I. systems are trained on copious amounts of human-generated data and designed to predict the next word in a given sentence. They are hilarious and eerie and at times dangerous.But what if, instead of building A.I. systems that mimic humans, we built those systems to solve some of the most vexing problems facing humanity?In 2020, Google DeepMind unveiled AlphaFold, an A.I. system that uses deep learning to solve one of the most important challenges in all of biology: the so-called protein-folding problem. The ability to predict the shape of proteins is essential for addressing numerous scientific challenges, from vaccine and drug development to curing genetic diseases. But in the 50-plus years since the protein-folding problem had been discovered, scientists had made frustratingly little progress.Enter AlphaFold. By 2022, the system had identified 200 million protein shapes, nearly all the proteins known to humans. And DeepMind is also building similar systems to accelerate efforts at nuclear fusion and has spun off Isomorphic Labs, a company developing A.I. tools for drug discovery.Demis Hassabis is the chief executive of Google DeepMind and the leading architect behind AlphaFold. So I asked him on the show to talk me through how AlphaFold actually works, the kinds of problems similar systems could solve and what an alternative pathway for A.I. development could look like.Mentioned:“The Curse of Recursion” by Ilia Shumailov, Zakhar Shumaylov, Yiren Zhao, Yarin Gal, Nicolas Papernot, Ross Anderson“DeepMind's CEO Helped Take AI Mainstream. Now He's Urging Caution” by Billy PerrigoBook Recommendations:The Fabric of Reality by David DeutschPermutation City by Greg EganConsider Phlebas by Iain M. BanksListen to this podcast in New York Times Audio, our new iOS app for news subscribers. Download now at nytimes.com/audioappThoughts? Guest suggestions? Email us at ezrakleinshow@nytimes.com.You can find transcripts (posted midday) and more episodes of “The Ezra Klein Show” at nytimes.com/ezra-klein-podcast, and you can find Ezra on Twitter @ezraklein. Book recommendations from all our guests are listed at https://www.nytimes.com/article/ezra-klein-show-book-recs.This episode of “The Ezra Klein Show” was produced by Rogé Karma. Fact checking by Michelle Harris. Fact checking by Michelle Harris with Rollin Hu. Our senior engineer is Jeff Geld. The show's production team also includes Emefa Agawu, Annie Galvin and Kristin Lin. Original music by Isaac Jones. Audience strategy by Kristina Samulewski and Shannon Busta. The executive producer of New York Times Opinion Audio is Annie-Rose Strasser. Special thanks to Sonia Herrero.
© 2020-2025 Ivy Podcast Discovery LLC
